SLS Stock Analysis: SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combina
- Latest close
- $11.59
- 20-day change
- -12.26%
- Trend state
- NEUTRAL
- Classification
- Healthcare · Biotechnology
Market context
SELLAS Life Sciences Group Inc moved -12.26% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.
Latest report
The latest cached company filing period (FY2025 · -$26.9M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.8/6, while Quality is the lowest at 1.2/6. Scores are comparative research signals, not forecasts.